Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
This webinar, presented by Dr. Kirsteen Maclean and Mark Burton, explores the optimization of immunohistochemistry (IHC) and digital pathology workflows in developing novel therapeutic antibody-drug conjugates (ADCs). Learn about current strategies and recent advances in using ADCs for early-phase oncology clinical trials, focusing on how these targeted cancer therapeutics deliver cytotoxic payloads to cancer cells while minimizing damage to healthy tissue. Discover the benefits of using IHC for ADC target and biomarker validation, understand the utility of validated IHC biomarker assays in screening and treatment decision-making, and explore how automation can enhance end-to-end workflows to answer critical research questions. The presenters share several oncology case studies highlighting how digital pathology techniques can identify patients with tumors expressing specific target antigens, ensuring ADC treatments are administered to the most likely responders. With Dr. Maclean's extensive experience in scientific affairs and Burton's expertise in life science and diagnostic solutions, this hour-long session provides valuable insights into streamlining customizable approaches to IHC for rapid and scalable biomarker assay discovery.
